ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
•17 Jan 2020 17:24

HK - Huge Sectoral Divergence in Shorts

We analyse the latest SFC data released today evening on short position reporting in Hong Kong for the week ended 10 January 2020.Total short...

Logo
460 Views
Share
bullish•Alibaba
•15 Jan 2020 10:06

Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do

2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...

Logo
722 Views
Share
bullish•Luckin Coffee
•12 Jan 2020 12:13

ECM Weekly (12 Jan 2020) - Jiumaojiu, I-Mab, Phoenix Tree, Burger King India

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We are...

Share
bearish•Wuxi Biologics
•09 Jan 2020 20:39

WuXi Biologics Placement: Pushing the Limits

Wuxi Biologics (Cayman) Inc (2269 HK)Ā is a global one-stop biologics services provider and often referred to as CRO (contract research...

Logo
546 Views
Share
bullish•Wuxi Biologics
•09 Jan 2020 18:14

Wuxi Biologics Placement: Almost All of the past Deals Have Done Well, Would Bid near the Bottom End

Wuxi Biologics Holdings is looking to raise upto US$672m by selling 4.2% of Wuxi Biologics (Cayman) Inc (2269 HK). This will be seventh placement...

Logo
645 Views
Share
x